Navigation Links
Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
Date:2/4/2013

MUMBAI, February 4, 2013 /PRNewswire/ --

- GBR 830 is the First Antagonistic Antibody Targeting OX40 and is a Potential Global First-in-class Molecule

- OX40, Also Known as CD134, Plays a Key Role in T-cell Mediated Autoimmune Disorders

Glenmark Pharmaceuticals S.A. (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 830, an anti-OX40 monoclonal antibody. GBR 830 has been discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 830, an anti-OX40 monoclonal antibody is a potential Global First-in-class molecule.

OX40 is a well-known target and the development of OX40 antagonists has been very challenging. Glenmark has achieved a significant milestone with the successful generation of an antagonistic OX40 monoclonal antibody coupled with generation of data validating the role of OX40 in autoimmune diseases.

GBR 830 shows great promise to emerge as a valuable therapeutic option to treat patients suffering from immune pathologies such as autoimmune diseases like Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD).

Commenting on this milestone, Dr. Michael Buschle , Chief Scientific Officer & President - Biologics, Glenmark Pharmaceuticals mentioned, "GBR 830 is a tremendous achievement for us. No antagonistic antibodies targeting OX40 are currently in clinical stage of development. We are confident that the antibody expertise and product development capabilities of the Switzerland Biologics Research Centre will continue to enrich the Glenmark discovery pipeline."

About OX40

OX40 (CD134) is a member of the TNFR/TNF super family and is mainly expressed on activated CD4 and CD8 T cells as well as a number of other lymphoid and non-lymphoid cells. Costimulatory signals from OX40 to an activated T cell promote division and survival, augmenting the clonal expansion of effector and memory populations. OX40 mediated costimulatory signaling plays a central role in the development of multiple inflammatory and autoimmune diseases. Inhibiting these interactions can be used to treat these conditions. Conversely, agents that activate OX40 are being developed to activate T-cells to target cancer cells. No OX40 antagonistic antibodies are currently in clinical stage of development.

Glenmark's Novel Biologics Entity pipeline

With the addition of GBR 830 to the pipeline, Glenmark will now have three monoclonal antibodies in the Novel Biologics Entity (NBE) pipeline. First, GBR 500, a monoclonal antibody represents a first-in-class opportunity indicated for the treatment of Inflammatory Bowel Disease (IBD) and Multiple Sclerosis (MS). GBR 500 has been licensed to Sanofi and is in Phase II trials in the US. The second monoclonal antibody, GBR 900 targets the TrkA receptor for pain. This project is developed under license from Lay Line Genomics S.p.A., an Italian based Company. Monoclonal antibodies specific for TrkA represent a first-in-class opportunity for the treatment of chronic pain, which has a high level of unmet need. GBR 900 is in the pre-clinical stage of development and will be developed further by Glenmark Biologics Research Centre in Switzerland.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has a number of molecules in various stages of clinical development and is primarily focused in the areas of Inflammation (asthma/COPD, rheumatoid arthritis etc.) and Pain (neuropathic pain and inflammatory pain). The company has a significant presence in branded generics markets across emerging economies including India. Through its subsidiary, Glenmark Generics Limited it has a significant present in the US and is among the leading generics organization in the country.

Primary Media Contact: Corporate Communications, corpcomm@glenmarkpharma.com, 91-22-40189999


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on ... that Charles W. Stellar has been named by the WEDI Board of Directors as ... As an executive leader with more than 35 years of experience in healthcare, association ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
(Date:5/24/2016)... Rockville, Maryland (PRWEB) , ... May 24, 2016 ... ... introduction of a newly re-branded identity. The new Media Cybernetics corporate branding reflects ... the world of imaging and image analysis. The re-branding components include a crisp, ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):